Cortexyme, Inc.
1609 Kirkham St.
San Francisco
California
94122
United States
Tel: 415-279-3644
Fax: 415-358-5888
Website: http://www.cortexyme.com/
23 articles with Cortexyme, Inc.
-
A summary of IPOs from companies in the biotech and pharma world since May 1, 2019.
-
Cortexyme, Inc. Announces Closing of Initial Public Offering and the Exercise of the Underwriters’ Option to Purchase Additional Shares
5/13/2019
Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat a key underlying cause of Alzheimer’s and other degenerative diseases, today announced the closing of its initial public offering of 4,412,000 shares
-
Cortexyme, Inc. Announces Pricing of Initial Public Offering
5/9/2019
Cortexyme, Inc. announced that it has priced its initial public offering of 4,412,000 shares of its common stock at a price to the public of $17.00 per share, before underwriting discounts and commissions.
-
Latham & Watkins Advises the Underwriters in the Initial Public Offering by Cortexyme
5/9/2019
Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat a key underlying cause of Alzheimer’s and other degenerative diseases, has announced that it has priced its initial public offering of 4,412,000 shares of its common stock at a price to the public of $17.00 per share, before underwriting discounts and commissions, as detailed in the company press release.
-
Four biotech companies began trading on the Nasdaq this morning. Here's a look at today’s launches and one rumored IPO.
-
A summary of IPOs from companies in the biotech and pharma world since April 1, 2019.
-
Cortexyme Announces Phase 2/3 Clinical Trial Based on Transformational Understanding of Alzheimer’s Disease Now Open for Enrollment
4/16/2019
The GAIN Trial will assess whether a new investigational medicine targeting P. gingivalis bacteria can slow or halt progression of Alzheimer’s disease
-
Although 2018 marked a record year for biopharma initial public offerings (IPO), 2019 has had a number of IPOs so far as well. Here’s a look at four recent IPO filings—and $86 million appears to be the magic number.
-
Cortexyme Elects Christopher J. Senner to Its Board of Directors
4/4/2019
Cortexyme, Inc. announced the election of veteran biopharma finance executive Christopher J. Senner to the company’s Board of Directors.
-
Cortexyme to Present Preclinical and Clinical Data Supporting Its Novel Investigational Alzheimer’s Treatment At AD/PD 2019
3/25/2019
Cortexyme, Inc. announced it will convene an educational session at AD/PD™ 2019, the 14th International Conference on Alzheimer’s & Parkinson’s Diseases, which is taking place March 26-31 in Lisbon, Portugal.
-
Biopharma Veterans Kevin Young and Una Ryan Join Cortexyme Board of Directors
2/11/2019
The experienced biopharmaceutical executives join Cortexyme’s board following a foundational publication in Science Advances and as lead compound COR388 advances into late-stage clinical development in mild-to-moderate AD.
-
February 1 Research Roundup: Alzheimer’s, Gum Disease and Gut Bacteria, New Understanding of Chol...
2/1/2019
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them. -
Sometimes it seems like just about every disease, including heart attacks, have been linked to gum disease. And sometimes it seems like just about everything from aluminum pots to herpes virus has been linked to Alzheimer’s.
-
Cortexyme Announces Key Leadership Appointments in Clinical Development and Finance to Support Next Stage of Growth
1/3/2019
Veteran clinical development professional Michael Detke, M.D., Ph.D., has been appointed Chief Medical Officer and Chris Lowe, a longtime life sciences finance expert, is now the company’s Chief Financial Officer
-
It has been six years since Johnson & Johnson first launched its JLABS incubators for the life science industry with a vision of providing assistance to startups that could potentially bring about a new paradigm of care for patients.
-
Cortexyme Announces Phase 1 Data Demonstrating COR388 is Safe and Well Tolerated in Healthy Older Volunteers and Alzheimer’s Patients
10/24/2018
Data on safety and exploratory cognitive testing presented in late-breaking poster at the 2018 Clinical Trials of Alzheimer’s Disease Conference
-
CLSA Names Pantheon DiNA Award Winners
10/9/2018
Bristol-Myers Squibb, Nektar Therapeutics, Amgen and others will be recognized for their significant contributions to the California life sciences industry during the November 2018 Pantheon DiNA Awards hosted by the California Life Sciences Association. -
Cortexyme Assembles World Class Clinical Advisory Board to Support Its Alzheimer’s Disease Clinical Development Program
9/27/2018
ortexyme, Inc., a clinical-stage pharmaceutical company developing therapeutics to alter the course of Alzheimer’s disease (AD) and other degenerative diseases, announced the formation of a new Clinical Advisory Board (CAB) in preparation for starting phase 2 clinical development in AD next year.
-
Alzheimer’s Company Cortexyme Closes $76 Million Series B Financing Round with Pfizer, Takeda and...
5/31/2018
South San Francisco-based Cortexyme closed on a $76 million Series B financing round. -
Cortexyme Completes $76 Million Series B Financing and Provides Update on Clinical Development Progress
5/31/2018
Cortexyme has successfully completed key components of its phase 1 clinical development program for lead compound COR388